1. Home
  2. LPX vs ACAD Comparison

LPX vs ACAD Comparison

Compare LPX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Louisiana-Pacific Corporation

LPX

Louisiana-Pacific Corporation

N/A

Current Price

$65.79

Market Cap

4.6B

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$19.71

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LPX
ACAD
Founded
1973
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.4B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
LPX
ACAD
Price
$65.79
$19.71
Analyst Decision
Buy
Buy
Analyst Count
14
20
Target Price
★ $91.79
$31.95
AVG Volume (30 Days)
1.1M
★ 2.0M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
★ 1.84%
N/A
EPS Growth
N/A
★ 69.12
EPS
★ 0.76
0.20
Revenue
★ $2,708,000,000.00
$726,437,000.00
Revenue This Year
N/A
$18.72
Revenue Next Year
$11.71
$12.62
P/E Ratio
★ $85.61
$97.90
Revenue Growth
N/A
★ 40.45
52 Week Low
$62.18
$19.32
52 Week High
$100.34
$30.96

Technical Indicators

Market Signals
Indicator
LPX
ACAD
Relative Strength Index (RSI) 45.89 18.16
Support Level $65.76 N/A
Resistance Level $76.95 $22.72
Average True Range (ATR) 2.10 0.84
MACD 0.22 -0.19
Stochastic Oscillator 55.59 4.77

Price Performance

Historical Comparison
LPX
ACAD

About LPX Louisiana-Pacific Corporation

Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: